Journal of Pain and Symptom Management
Volume 38, Issue 4 , Pages 515-521 , October 2009

Frequency of Long-Acting Opioid Analgesic Initiation in Opioid-Naïve Nursing Home Residents

  • David M. Dosa, MD, MPH

      Affiliations

    • Center for Gerontology and Health Care Research, The Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA
    • Veterans Administration Medical Center, Rhode Island Hospital, Providence, Rhode Island, USA
    • Division of Geriatrics, Rhode Island Hospital, Providence, Rhode Island, USA
    • Corresponding Author InformationAddress correspondence to: David Dosa, MD, MPH, Division of Geriatrics, Brown University, Rhode Island Hospital, 593 Eddy Street, APC 424, Providence, RI 02903, USA.
  • ,
  • David D. Dore, PharmD, PhD

      Affiliations

    • Department of Community Health, The Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA
    • i3 Drug Safety, Waltham, Massachusetts, USA
  • ,
  • Vincent Mor, PhD

      Affiliations

    • Center for Gerontology and Health Care Research, The Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA
    • Department of Community Health, The Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA
  • ,
  • Joan M. Teno, MD, MS

      Affiliations

    • Center for Gerontology and Health Care Research, The Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA
    • Department of Community Health, The Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA
    • Division of Geriatrics, Rhode Island Hospital, Providence, Rhode Island, USA

,Accepted 10 December 2008.

References 

  1. A public health advisory: safety warnings regarding use of fentanyl transdermal (skin) patches. Available from http://www.fda.gov/cder/drug/advisory/fentanyl.htmAccessed September 14, 2007
  2. Package insert: Duragesic®. Available from http://www.fda.gov/cder/drug/infopage/fentanyl/DuragesicPPI.pdfAccessed January 17, 2008
  3. Package insert: Oxycontin®. Available from http://www.fda.gov/cder/foi/label/2006/020553s056lbl.pdfAccessed January 17, 2008
  4. Package insert: MS Contin®. Available from http://www.fda.gov/medwatch/safety/2007/May_PI/MSContin_PI.pdfAccessed January 17, 2008
  5. Guay DR, Artz MB, Hanlon JT, Schmader KE. The pharmacology of aging. In:  Tallis RC,  Fillit HM editor. Brocklehurst's textbook of geriatric medicine and gerontology. New York: Churchill Livingstone; 2003;p. 155–161
  6. Institute of Medicine . Preventing medication errors. Washington, DC: National Academy Press; 2006;
  7. Gurwitz JH, Field TS, Hudge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118:251–258
  8. Ruths S, Straand J, Nygaard HA. Multidisciplinary Medication review in nursing home residents: what are the most significant drug related problems? The Bergen District Nursing Home (BEDNURS) study. Qual Saf Health Care. 2003;12:176–180
  9. Mills PD, Neily J, Kinney LM, Bagian J, Weeks WB. Effective interventions and implementation strategies to reduce adverse drug events in the Veterans Affairs (VA) system. Qual Saf Health Care. 2008;17:37–46
  10. Nowak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med. 2004;5:59–65
  11. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA. 2000;283:1710–1714
  12. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol. 2000;53:1248–1257
  13. Rigler SK, Shireman TI, Kallenbach L. Predictors of long acting opioid use and oral versus transdermal route among older Medicaid beneficiaries. Am J Geriatr Pharmacother. 2007;5(2):91–99
  14. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001;22:672–687
  15. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing. Conversion dilemmas. J Pain Symptom Manage. 2001;21:397–406
  16. American Pain Society . Principles of analgesic use in the treatment of acute pain and cancer pain. 4th ed.. Glenview, IL: American Pain Society; 1999;
  17. Morris JN, Hawes C, Fries BE, et al. Designing the national resident assessment instrument for nursing homes. Gerontologist. 1990;30:293–307
  18. Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol Med Sci. 1999;54:M546–M553
  19. Hartmaier SL, Sloane PD, Guess HA, et al. Validation of the minimum data set Cognitive Performance Scale: agreement with the mini-mental state examination. J Gerontol A Biol Sci Med Sci. 1995;50:M128–M133
  20. Institute of Medicine . To err is human: Building a safer health care system. Washington, DC: National Academy Press; 2000;
  21. Mystakidou K, Parpa E, Tsilika E, et al. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. J Pain. 2004;5:119–132

 This work was supported by grant number 5T32HS000011-21 from the Agency for Health Care Research and Quality (PI Dr. Mor, Dr. Dore supported).Dr. Dore conducted this work while an employee of Brown University and, during this time, received consultancy fees from Pfizer, Inc. and i3 Drug Safety for work independent of this study. Drs. Dosa, Mor, and Teno have no disclosures to report.Dr. Dore had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article.

PII: S0885-3924(09)00306-6

doi: 10.1016/j.jpainsymman.2008.11.008

Journal of Pain and Symptom Management
Volume 38, Issue 4 , Pages 515-521 , October 2009